Significance of Galectin-3 and N-terminal pro B-type natriuretic peptide in the prediction of atrial fibrillation after cardiac surgery

Biomarkers and post-operative atrial fibrillation

  • Nikola Mladenovic Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
  • Ranko University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Lazar University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Vanja University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Mirko University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Maletin University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia
  • Aleksandra Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
  • Nemanja Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia
  • Bogdan Institute of Cardiovascular Diseases Dedinje, Belgrade, Serbia
  • Valentina University of Nis, Faculty of Medicine, Nis, Serbia
  • Milan University of Nis, Faculty of Medicine, Nis, Serbia
  • Dane University of Nis, Faculty of Medicine, Nis, Serbia
  • Aleksandar University of Nis, Faculty of Medicine, Nis, Serbia
  • Marko University of Nis, Faculty of Medicine, Nis, Serbia
  • Kamenov University of Nis, Faculty of Medicine, Nis, Serbia
DOI: https://doi.org/10.5937/jomb0-47001
Keywords: Post-operative atrial fibrillation, Cardiac surgery, Galectin-3, NT-proBNP

Abstract


Background: Post-operative atrial fibrillation (POAF) is a frequent complication after cardiac surgery. It is associated with prolonged hospital stay, increased morbidity, mortality rate and economic costs. The aim of the study was to determine the association between the values of Galectin-3 and N-terminal pro-B-type natriuretic peptide (NT-proBNP) with POAF after cardiac surgery.

Patients and methods: A prospective study enrolled patients aged 18-85 years old admitted due to elective coronary artery bypass graft surgery (CABG) or CABG + aortic valve replacement. The plasma Galectin-3 and NT-proBNP levels were measured one day before surgery postoperative days 1 and 7. 

Results: The study included a total of 103 patients. POAF was registered in 45 patients. The mean age of patients in whom POAF occurred was 68.8 years, while other patients’ mean age was 65.5 years (p=0.028). Patients with POAF did not differ from the group without POAF in the values of Galectin-3 and NT-proBNP preoperatively as well as on the first and seventh postoperative days. Changes in Galectin-3 levels on the first postoperative day had statistically significant value for predicting POAF (AUC=0.627 [0.509-0.745], p<0.05). Decrease in Galectin-3 level concentration on the first postoperative day over 17% increases the risk of developing AF.

Conclusion: Preoperative values of Galectin-3 and NT-proBNP are not associated with POAF development after cardiac surgery. The only association we found is that reduced values of Galectin-3 on the first postoperative day for over 17% may actually be a POAF predictor.

Author Biographies

Ranko, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Asistent in the departmant Anesthesiology with resuscitation.

Lazar, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Professor  at the department od Surgery

Vanja, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Assistant at the Department of Internal Medicine

Mirko, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Assistant at Department of Internal Medicine

Maletin, University of Novi Sad, Faculty of Medicine, Novi Sad, Serbia

Assistant of Department of Internal Medicine

Aleksandra, Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia

Physician at the Cardiovascular surgery clinic.

Nemanja, Institute of Cardiovascular Diseases of Vojvodina, Sremska Kamenica, Serbia

Physician at the Cardiovascular surgery clinic.

Bogdan, Institute of Cardiovascular Diseases Dedinje, Belgrade, Serbia

Cardiac surgeon

Valentina, University of Nis, Faculty of Medicine, Nis, Serbia

Professor at department of Pharmacology

Milan, University of Nis, Faculty of Medicine, Nis, Serbia

Professor at the Department of Internal medicine

Dane, University of Nis, Faculty of Medicine, Nis, Serbia

Assistant professor at the Department of Pharmacology

Aleksandar, University of Nis, Faculty of Medicine, Nis, Serbia

Assistant at Department of Anesthesiology and rescutitation

Marko, University of Nis, Faculty of Medicine, Nis, Serbia

Assistant at Department of Surgery

Kamenov, University of Nis, Faculty of Medicine, Nis, Serbia

Assistant at Department of Surgery

References

1.         Obrenović-Kirćanski B, Orbović B, Vraneš M, Parapid B, Kovačević-Kostić N, Velinović M, at al. Atrial fibrillation after coronary artery bypass surgery: Possibilities of prevention. Srp Arh Celok Lek 2012; 140: 521-527.


2.         Halonen J, Kärkkäinen J, Jäntti H, Martikainen T, Valtola A, Ellam S, at al. Prevention of Atrial Fibrillation After Cardiac Surgery: A Review of Literature and Comparison of Different Treatment Modalities. Cardiol Rev 2022; Online ahead of print.


3.         Charitakis E, Tsartsalis D, Korela D, Stratinaki M, Vanky F, Charitos EI, at al. Risk and protective factors for atrial fibrillation after cardiac surgery and valvular interventions: an umbrella review of meta-analyses. Open Heart 2022; 9: e002074.


4.         Cai M, Schotten U, Dobrev D, Heijman J. Atrial fibrillation substrate development before, during and after cardiac surgery: Who is to blame for late post-operative atrial fibrillation? Int J Cardiol 2022; 365: 44-46.


5.         Hernández-Romero D, Vílchez JA, Lahoz Á, Romero-Aniorte AI, Jover E, García-Alberola A, at al. Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation. Sci Rep 2017; 7: 40378.


6.         Werhahn SM, Becker C, Mende M, Haarmann H, Nolte K, Laufs U, at al. NT-proBNP as a marker for atrial fibrillation and heart failure in four observational outpatient trials. ESC Heart Failure 2022; 9: 100–109.


7.         Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomström-Lundqvist C, at al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42: 373-498.


8.         Rezk M, Taha A, Nielsen SJ, Gudbjartsson T, Bergfeldt L, Ahlsson A, at al. Clinical Course of Postoperative Atrial Fibrillation After Cardiac Surgery and Long-term Outcome. Ann Thorac Surg 2022; 114:2209-2215.


9.         Fleet H, Pilcher D, Bellomo R, Coulson TG. Predicting atrial fibrillation after cardiac surgery: a scoping review of associated factors and systematic review of existing prediction models. Perfusion 2023; 38: 92-108.


10.       Erdem K, Kurtoglu E, Oc M, Oc B, Ilgenli TF, Unlu A, at al. The plasma galectin-3 level has high specificity and sensitivity for predicting postoperative atrial fibrillation after coronary artery bypass surgery. Eur Rev Med Pharmacol Sci 2022; 26:9072-9078.


11.       Sygitowicz G, Maciejak-Jastrzębska A, Sitkiewicz D. The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases. Biomolecules. 2021; 12:46.


12.       Castiglione V, Aimo A, Vergaro G, Saccaro L, Passino C, Emdin M. Biomarkers for the diagnosis and management of heart failure. Heart Fail Rev 2022; 27: 625-643.


13.       Tian L, Chen K, Han Z. Correlation between Galectin-3 and Adverse Outcomes in Myocardial Infarction Patients: A Meta-Analysis. Cardiol Res Pract 2020; 2020: 7614327.


14.       Richter B, Koller L, Hofer F, Kazem N, Hammer A, Silbert BI, at al. Galectin-3 is an independent predictor of postoperative atrial fibrillation and survival after elective cardiac surgery. Heart Rhythm 2022; 19: 1774-1780.


15.       Patel DM, Thiessen-Philbrook H, Brown JR, McArthur E, Moledina DG, Mansour SG, at al. Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. American Heart Journal 2020; 220: 253-263.


16.       Polineni S, Parker DM, Alam SS, Thiessen-Philbrook H, McArthur E, DiScipio AW, at al. Predictive Ability of Novel Cardiac Biomarkers ST2, Galectin-3, and NT-ProBNP Before Cardiac Surgery. J Am Heart Assoc 2018; 7: e008371.


17.       Gong M, Cheung A, Wang QS, Li G, Goudis CA, Bazoukis G, at al. Galectin-3 and risk of atrial fibrillation: A systematic review and meta-analysis. Journal of Clinical Laboratory Analysis. 2020; 34: e23104.


18.       Xu Z, Qian L, Zhang L, Gao Y, Huang S. Predictive value of NT-proBNP, procalcitonin and CVP in patients with new-onset postoperative atrial fibrillation after cardiac surgery. Am J Transl Res 2022; 14: 3481-3487.


19.       Gasparovic H, Burcar I, Kopjar T, Vojkovic J, Gabelica R, Biocina B, at al. NT-pro-BNP, but not C-reactive protein, is predictive of atrial fibrillation in patients undergoing coronary artery bypass surgery. Eur J Cardiothorac Surg 2010; 37: 100-105.

Published
2023/12/12
Issue
Vol. 43 No. 3 (2024): Journal of Medical Biochemistry
Section
Original paper

Copyright (c) 2023 Nikola Mladenovic, Ranok Zdravkovic, Lazar Velicki, Vanja Drljevic Todic, Mirko Todic, Srdjan Maletin, Aleksandra Mladenovic, Nemanja Petrovic, Bogdan Okiljevic, Valentina Nikolić, Milan Pavlovic, Dane Krtinic, Aleksandar Nikolic, Marko Gmijovic, Aleksandar Kamenov

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.